Oncocyte Profit Margin

The latest profit margin for OCX is -2955.63% as of June 2026. That compares with -1489.71% in the prior-year period — down 98.4% year over year. That is below the Technology sector average of 71.24%. Investors often review this figure alongside Oncocyte's historical trend and sector peers before judging valuation or financial health.

Over the past year, OCX's profit margin moved from -1489.71% to -2955.63% — a 98.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Oncocyte's valuation or profitability profile.

Against Technology companies, OCX currently prints -2955.63% for profit margin, while the sector average sits near 71.24%. That is roughly 4249.0% below the sector mean. Large gaps often invite a closer look at Oncocyte's growth, margins, and balance sheet.

Profit Margin shows how effectively Oncocyte converts resources into returns. At -2955.63%, OCX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1489.71% in the prior-year period — down 98.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting OCX's profit margin (-2955.63%), review year-over-year change from -1489.71%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.